Downloading...
Download

CUSTODIAN

$APYP R/M Into SleepX Could Make it a MASSIVE Runner PT: $1+On Nov 11th the company was successfully redomiciled to Nevada leaving just the last administrative steps towards the completion of the merger in December. twitter.com FRANCE Patent No. EP11819507.2 renewed in September twitter.com UK Patent No. EP2608717 renewed in September twitter.com Israeli Patent No. 224854 renewed in August twitter.com SleepX also has a portfolio of FIVE patents some of which are used in Fitbit: www.sleepxclear.com Intellectual property The company’s technology is protected by patents in order to provide a strong IP protection, one of the Company's most important assets. Its technology, applications and products, both in the medical and nonmedical fields, are protected by the laws of the United States and other jurisdictions worldwide. The Company's measurement technology utilizes a technique that measures a range of physical parameters as a function of time to a level of accuracy previously unattainable. The company's patent portfolio includes: ***SYSTEMS AND METHODS FOR SNORING DETECTION AND PREVENTION*** 1. ​HIGH-SENSITIVITY SENSORS FOR SENSING VARIOUS PHYSIOLOGICAL PHENOMENA, PARTICULARLY USEFUL IN ANTI-SNORING APPARATUS AND METHODS. 2. APPARATUS FOR USE IN CONTROLLING SNORING AND SENSOR UNIT PARTICULARLY USEFUL THEREN. 3. APPARATUS AND METHOD FOR DIAGNOSING SLEEP QUALITY 4. ESTIMATION OF SLEEP QUALITY PARAMETERS FROM WHOLE NIGHT AUDIO ANALYSIS 5. APPARATUS AND METHOD FOR DIGNOSING OBSTRUCTIVE SLEEP APNEA With distinctive innovative sensor technologies and algorithms, the Company is well-positioned to become a market leader in the snoring and obstructive sleep apnea treatment markets. twitter.com twitter.com The company also signed an agreement with NewsDirect's PR Firm for upcoming press release and marketing capabilities once everything has been finalized and completed. twitter.com www.sleepxclear.com
OTC:APYPLong
by StockGuild
$IFXY 62% Owned by Krisa/Cooley Biggest R/M or Holding CmpyKrisa Management and Carey Cooley own 62% of all Common Shares twitter.com www.otcmarkets.com They have continually said that this will be their biggest merger out of all their shells twitter.com twitter.com In their most recent update they announced that the launch is getting closer and is almost ready. They are also working on two acquisitions already turning $IFXY into possibly a holding company for multiple acquisitions. twitter.com "The $IFXY launch is getting closer. @CareyCooley is working hard on a deal to get his preferred COO on board. We are also trying to negotiate deals for our first two acquisitions."
OTC:IFXYLong
by StockGuild
$LEAS Major Pharma Potential with Acquisitions lined up PT .50PHARMIA’s $LEAS goal is to become a leading generics and super-generics company within 5 years. In executing its Plan, PHARMIA will take a three stage approach to the achievement of its goals. Stage 1 In the initial stage, PHARMIA will launch the company by acquiring MAs in Europe and ANDAs in the United States for generic products that are essential medicines in chronic short supply. PHARMIA will use 3rd parties in Germany to manufacture our oncology products and we will commercialize these “supply challenged” products which generally are older but “mainstay” life-saving medications for the treatment of cancer and infectious diseases, to include the drug shortages caused by the COVID-19 pandemic, where PHARMIA’s team has particular expertise. We will build the drug portfolio and the PHARMIA “brand name” during Stage 1. Stage 2 In the second stage of PHARMIA’s strategic plan, the company will develop and commercialize a portfolio of novel branded “super-generics” (super-generics are “better than generics” as they have added value and are patented). To achieve this goal, PHARMIA will capitalize on its ownership of the active pharmaceutical ingredients (“API”) acquired in Stage 1, and utilize the scientific and technical development expertise of its team members to reformulate the API of those generics into patented formulations. The goal is to create novel, patentable formulations with novel and improved characteristics (such as extended release, dissolvable films and implants, multiple drug combinations in one pill, etc.) that are more patient friendly, and more easily administered. The development of a portfolio of “super-generics” during Stage 2 will be a major revenue driver going forward. This “value add” will enhance patient compliance and therapeutic outcomes, differentiating PHARMIA pipeline from the competition. Also during Stage 2, the acquisition and development of biologic medicines (“antibodies”) targeting oncology will have begun, with the company already licensing three antibodies that have been fully developed and are on the market in several countries. It is PHARMIA objective to start and complete Phase 3 clinical trials of each “biosimilar” antibody targeting breast cancer, colorectal cancers, brain cancers, and several other solid tumors. Stage 2 is an important growth phase for the company. Stage 3 In the third stage of growth, PHARMIA will focus its attention on acquiring its own manufacturing facilities in the USA for the production of Active Pharmaceutical Ingredients (APIs) and final, formulated Drug Product dosage forms. This will enable the company to totally control the whole supply chain process and also expand its portfolio of products that are, or are expected to be, in chronic short supply or suffering from ongoing quality issues when supplied from outside the USA or Europe. With its own manufacturing infrastructure in place, PHARMIA will have the capability to meet supply demand by expeditiously switching manufacturing from one product to another in the same facility with only minor process changes required. The company will expand its sterile injectable drug manufacturing capabilities and its solid dosage form (super-generics) capacity during Stage 3. Starting with high quality but low-cost, affordable generic drugs treating deadly diseases, the second phase of grow is by employing pharmaceutical drug delivery technologies to enhance and improve the generic drug incorporated in the drug formulation as a “super-generic”. Our super-generics employ a technology called “3-D screen printing” of drugs with extended release properties and will provide a sustained drug level within the “therapeutic window” for once-a-day dosing. A single pill containing three or four medicines that can be taken once-a-day, and this approach provides the patient a lower “pill burden” and this will result in better compliance in taking the medicine and overall improved care of the patient. The company is working on 3-D screen-printed medicines with novel dissolution and release characteristics. 3-D screen-printing technology opens up new, flexible and versatile options for the pharmaceutical industry in the manufacturing process of their products. Thousands or even millions of medical doses can be manufactured per machine per year. The 3-D screen-printing process allows for many different kinds of shapes, sizes and compositions. We are committed to maintaining our entire business operations including the 3-D screen printing commercial manufacturing in America, Canada, and/or Europe (Ireland and Germany), and we will continue to build strong, lasting relationships with European and our Nation’s largest pharmacy chains, wholesalers, and distributors. Essential Medicines – Affordable Prices investorshub.advfn.com Dr. Joseph Sinkule Co-Founder, Chief Executive Officer (CEO) and Director www.pharmia-inc.com Strategic Asset Leasing Inc. Announces Cryptocurrency Launch Press Release | 10/06/2020 Strategic Asset Leasing Inc. Announces Cryptocurrency Development Press Release | 10/02/2020 Strategic Asset Leasing Inc. Enters Into MOU Press Release | 09/30/2020 Strategic Asset Leasing Inc. Announces New Subsidiary Press Release | 09/29/2020 Strategic Asset Leasing Inc. Enters Into Additional LOI Press Release | 09/25/2020 Strategic Asset Leasing Inc. Joins Open Source Projects Press Release | 09/24/2020
LLong
by StockGuild
$DLPX $7 Mil+ HQ and Sub of NASDAQ $AIRT On the Move Flwg UpdtsTaken from their website: “Delphax Solutions, Inc. is a business unit of holding company AIR T, INC. , which has been established since 1980.” www.delphaxsolutions.com $AIRT is currently trading at $26.77 This statement is from the Financial Q10 of February 12, 2021 AIRT: Type of Revenue Nature, Timing of Satisfaction of Performance Obligations, and Significant Payment Terms Product Sales The Company generates revenue from sales of various distinct products such as parts, aircraft equipment, >>>printing equipment<<<, jet engines, airframes, and scrap metal to its customers. A performance obligation is created when the Company accepts an order from a customer to provide a specified product. Each product ordered by a customer represents a performance obligation. Here is the link for the location of its HQ and you will see the warehouse and the sign Delphax. The warehouse building alone should be worth more than $7 million. See it yourself: goo.gl
OTC:DLPXLong
by StockGuild
$MEGH Potential For Massive Gains With Upcoming Custodianship$MEGH Has been getting steadily accumulated ahead of the upcoming Custodianship by Small Cap Compliance LLC's Rhonda Keaveney: www.smallcapcompliance.com The shell is perfect in every way boasting a massively impressive small S/S: 50 Mil A/S 49 Mil O/S 25,800,000 of which is restricted and a 17 Mil or less Float. The stock has been moving upwards the last few days and is in breakout mode on the charts. I anticipate a move to around .25-.30 the day of the Custodianship announcement and a slow move to over a $1 in the weeks after. The small S/S is perfect for a major move and presents immense trading opportunities. All IMO. PT: $1+
OTC:MEGHLong
by StockGuild
$SMEV Synergy Plans on Working with Company Management PT .25$SMEV Synergy dropped the news the other day that they would be discussing options as far as working with Synergy management to bring a company in or a acquisition following the COO's decision that he would like to keep the shell. This news brings the best of both worlds as the COO was pivotal in the development of the company's Spa Capsules a few years ago which were successful. Ben of Synergy owns 24,000,000 shares of the Company's common stock and the COO Allen owns Preferred shares so it would benefit them both if they worked together to get the company streamlined and back up and running with a new R/M'ed company that Synergy probably already has lined up for the shell. I see this as a win win although many saw it as possible "Bad news" and sold the last couple days the stock has regained traction and the selling has all but finished with the stock moving green several times today. Personal PT of .25 is still on track IMO.
OTC:SMEVLong
by StockGuild
$SMEV Synergy President Owns 3% of O/S Major Custodian Update$SMEV Has been on the move carefully moving upwards towards its breakout point anticipated to be Feb 1st or much sooner as the company updated yesterday that the court has published their custodianship giving anybody 30 days to contest, after which they will more than likely receive it as the current owners couldn't be found and it is 100% theirs after the 30 day period. This is probably the best custodian out of all the Synergy shells and one with the best history. The current S/S is optimal for a major R/M as everything is small with a somewhat large A/S that may be reduced to the liking of whatever company they decide to put in it. Synergy has been on the ball with R/M's and Custodianships and is renown in the OTC as the best. I anticipate the stock to continue north possibly breaking .01 by the time the 30 days are up and the company announces it has the custodian, after which the stock could possibly breakout that same day to .05 or higher. After that it will probably trend towards .25+ as the R/M is announced, filings drop and PR's begin hitting. At these levels groups are currently loading in anticipation of what is to come.
OTC:SMEVLong
by StockGuild